All News

New recommendations from the American Academy of Neurology and American Headache Society give providers clearer criteria for preventive migraine therapy.

Presenting what they believe are the problems and solutions, PCMA CEO David Marin and NCPA CEO Douglas Hoey, RPh, discuss the US drug pricing dilemma.

The 4 key organizations regularly focusing on respiratory virus season released updated vaccine recommendations for 2026-2027.

As data reframes vaccines as a lifelong tool, pharmacists are becoming the access point that keeps patients up to date at every stage of life.

Scott Stoll and Kenzie Hohman, PharmD, discuss the importance of pharmacy advocacy, from localized efforts to federal movement across the profession.

Community pharmacists use a quick migraine toolkit to spot symptoms early, guide OTC care, and refer patients, aiming to prevent chronic migraines.

Independent pharmacist Tom DePietro explains how shifting vaccine policies, ACIP changes, and patient confusion are reshaping immunization at the pharmacy counter.

The American Pharmacists Association, Canadian Pharmacists Association, and International Pharmaceutical Federation release plans for pharmacists’ primary care integration.

JD Power releases its US Pharmacy Digital Experience Study, highlighting the growing importance of digital solutions in pharmacy practice and business.

Kelly Goode examines 2026–27 vaccine guidance for pharmacists, detailing updated flu, COVID-19, and RSV recommendations and coadministration.

In part 2, Scott Stoll and Kenzie Hohman, PharmD, explain their respective advocacy efforts, highlighting the sheer range of a profession fighting for change.

Live attenuated influenza vaccine increased pneumococcal density in vaccinated children, raising odds of pneumococcal infection among household contacts.

Kenzie Hohman, PharmD, and Scott Stoll believe pharmacy advocacy is inherent in its workforce, despite the constant and deterrent pressures it faces.

The federal government is actively looking to enhance its evolving approach toward US childhood vaccine recommendations.

The first new US sunscreen active ingredient in years is reaching shelves through dsm-firmenich's Parsol Shield and Ultra Violette's new SPF launch.

Data show starting antivirals within 48 hours of symptom onset sharply lowers pediatric hospitalization risk.

The approval gives pharmacists a new nonTNF biologic option across both major forms of pediatric inflammatory bowel disease.

With previous approvals for weight loss and sleep apnea, tirzepatide is opening doors to a healthier well-being for patients living with type 2 diabetes.

Pfizer and BioNTech, Moderna, Sanofi, and Takeda received FDA approval for updated 2026-2027 COVID-19 vaccines reformulated to target the XFG variant.

New consensus confirms that chronic obstructive pulmonary disease, asthma, bronchiectasis, and lung cancer are indications for pneumococcal vaccination.

This fall’s event will focus on the expanding role of pharmacists in providing patient care with clinical value, prevention, and more.

Researchers identify the resources and opportunities available for community pharmacies to incorporate climate-conscious health care practices.

A study links dormant virus reactivation during COVID-19 hospitalization to inflammation-driven immune changes and long COVID disability.

Focusing on serotype distribution, resistance trends, and vaccination impact, researchers analyze invasive pneumococcal disease burden.

A study found that community pharmacists are viewed as medication dispensers, with gaps in awareness screening, counseling, and other prevention services.

Exploring rural and urban density data, and the factors that lead to it, researchers review community pharmacy prominence across Australia.

The combination of bictegravir and lenacapavir gives virologically suppressed adults with HIV a new option showing sustained viral suppression.

The once daily medication outperformed placebo across all 9 key secondary end points in the phase 3 VALOR trial.